Alnylam to Host Eighth Annual “RNAi Roundtable” Webcast Series
June 23 2021 - 7:00AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that it plans to host its 8th
annual series of “RNAi Roundtable” webinars over the coming weeks.
The series will offer a range of presentations from Alnylam
scientists and program leaders who will review recent progress in
many of the Company’s pipeline programs and platform innovations,
as well as medical thought leaders who will provide their
perspectives on clinical developments and unmet needs in various
therapeutic areas. Each event will be webcast live on the Investors
section of the Company’s website at www.alnylam.com/events, and a
replay will be posted on the Alnylam website approximately three
hours after each event.
The 2021 RNAi Roundtable schedule is as follows:
- ALN-AGT, in Development for the Treatment of
Hypertension Wednesday, June 30, 10:00 am ET
- Patisiran and Vutrisiran, in Development for the Treatment
of ATTR Amyloidosis Friday, July 16, 11:00 am ET
- Givosiran, for the Treatment of Acute Hepatic Porphyria
Wednesday, August 4, 1:30 pm ET
- Lumasiran, for the Treatment of Primary Hyperoxaluria Type
1 Thursday, August 19, 9:30 am ET (tentative)
- Liver-Directed RNAi Pipeline Programs Monday, September
20, 11:00 am ET
- CNS & Extrahepatic RNAi Pipeline Programs Friday,
October 1, 1:30 pm ET
Please visit the Capella section of our website for the latest
information regarding webcast dates.
About RNAi
RNAi (RNA interference) is a natural cellular process of gene
silencing that represents one of the most promising and rapidly
advancing frontiers in biology and drug development today. Its
discovery has been heralded as “a major scientific breakthrough
that happens once every decade or so,” and was recognized with the
award of the 2006 Nobel Prize for Physiology or Medicine. By
harnessing the natural biological process of RNAi occurring in our
cells, a new class of medicines, known as RNAi therapeutics, is now
a reality. Small interfering RNA (siRNA), the molecules that
mediate RNAi and comprise Alnylam’s RNAi therapeutic platform,
function upstream of today’s medicines by potently silencing
messenger RNA (mRNA) – the genetic precursors – that encode for
disease-causing proteins, thus preventing them from being made.
This is a revolutionary approach with the potential to transform
the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA
interference (RNAi) into a whole new class of innovative medicines
with the potential to transform the lives of people afflicted with
rare genetic, cardio-metabolic, hepatic infectious, and central
nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning
science, RNAi therapeutics represent a powerful, clinically
validated approach for the treatment of a wide range of severe and
debilitating diseases. Founded in 2002, Alnylam is delivering on a
bold vision to turn scientific possibility into reality, with a
robust RNAi therapeutics platform. Alnylam’s commercial RNAi
therapeutic products are ONPATTRO® (patisiran), GIVLAARI®
(givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran) being
developed and commercialized by Alnylam’s partner Novartis. Alnylam
has a deep pipeline of investigational medicines, including six
product candidates that are in late-stage development. Alnylam is
executing on its “Alnylam P5x25” strategy to deliver transformative
medicines in both rare and common diseases benefiting patients
around the world through sustainable innovation and exceptional
financial performance, resulting in a leading biotech profile.
Alnylam is headquartered in Cambridge, MA. For more information
about our people, science and pipeline, please visit
www.alnylam.com and engage with us on Twitter at @Alnylam, on
LinkedIn, or on Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210623005252/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media) 617-682-4340 Josh Brodsky (Investors)
617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024